FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer

The FDA has granted accelerated approval to the combination of avutometinib and defactinib for adults with KRAS-mutated, recurrent, low-grade serous ovarian cancer who have previously received systemic therapy. The efficacy was evaluated in a trial, and the recommended doses for both drugs were provided.